Breast Cancer Coverage from Every Angle
Advertisement
Advertisement

Treatment Implications of Breast Tumors’ Switch to HER2-Low Status in Recurrence

By: Vanessa A. Carter, BS
Posted: Tuesday, June 22, 2021

Federica Miglietta, MD, of the University of Padova, Italy, and colleagues presented findings from reportedly the first study to determine how breast cancers evolve from HER2-negative primaries to HER2-low recurrent tumors during the European Society for Medical Oncology (ESMO) Breast Cancer Virtual Congress 2021 (Abstract 4MO_PR). Specifically, approximately 29% of patients converted to, or from, HER2-low status, and the researchers noted that this expression is unstable during the evolution of breast cancer.

“The results provide a whole new insight on how HER2-low tumors might evolve as a subgroup, possibly challenging the current dichotomy between HER2-positive and HER2-negative breast cancer,” stated Dr. Miglietta in an ESMO press release. “Our findings stress the importance of re-testing HER2 expression on tumor relapse since it might provide the option of new therapeutic opportunities, currently in a trial, and hopefully in the near future, in the clinic.”

The investigators focused on samples from 575 patients with matched primary and relapsed breast cancers. Primary tumor types included HER2-negative/hormone receptor (HR)-positive (luminal-like, 59%), HER2-positive (25%), and triple-negative (16%). Cases that were HER2-negative were classified as HER2-low or HER2-0.

The rates of HER2-low cases in primary and relapsed tumors were 34% and 38%, respectively. HER2-low status in primary and relapsed samples was more common in HER2-negative/HR-positive (47% and 54%) and triple-negative (41% and 40%) tumors (P = .006). With HER2-0 switching to HER2-low (15%) and HER2-low switching to HER2-0 (14%), the overall rate of HER2 discordance was 38%.

About 9% of cases acquired or lost HER2 positivity. Patients who had a HER2-negative tumor that was luminal-like had a HER2 discordance rate of 45%, whereas those with triple-negative disease had a rate of 35% (P = .080); this was notably due to cases switching from HER2-0 to HER2-low in 40% of HER2-negative/HR-positive and 24% of triple-negative cases (P = .088).

Disclosure: For full disclosures of the study authors, visit oncologypro.esmo.org.



By continuing to browse this site you permit us and our partners to place identification cookies on your browser and agree to our use of cookies to identify you for marketing. Read our Privacy Policy to learn more.